2024-10-05 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a multinational healthcare company that develops, manufactures, and markets a diverse range of medical devices, pharmaceuticals, and nutritional products.

**Performance Analysis:**

**1. Return vs. S&P 500:**

* ABT's cumulative return is 103.46%, while the S&P 500 (VOO) has a cumulative return of 131.45%. 
* This indicates ABT has underperformed the S&P 500 by **-27.99%** over the period analyzed.
* The relative divergence of -27.99% indicates that ABT's performance has been **14.28%** lower than the S&P 500 compared to its historical performance range.

**2. Recent Price Movement:**

* Closing price: $113.64
* 5-day moving average: $113.33
* 20-day moving average: $114.77
* 60-day moving average: $110.50

The stock price is currently trading slightly below the 5-day and 20-day moving averages, suggesting potential for a short-term correction. However, it is above the 60-day moving average, indicating a longer-term upward trend.

**3. Technical Indicators:**

* **RSI:** 35.81 - This suggests the stock is currently in the neutral zone, indicating neither overbought nor oversold conditions.
* **PPO:** -0.38 - A negative PPO suggests that the price momentum is weakening, potentially signaling a short-term downward trend.
* **Delta_Previous_Relative_Divergence:** -6.68 -  This negative value implies a recent downward trend in the relative divergence, suggesting that ABT's performance has been lagging the S&P 500 over the past 20 days.
* **Expected Return:** 0.0% - This represents the projected 5-year expected return relative to the S&P 500, suggesting minimal potential for outperforming the market in the long term.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue        |
|------------|----------|----------------|
| 2024-07-31 | 0.74     | $10.38 Billion  |
| 2024-05-02 | 0.70     | $9.96 Billion  |
| 2023-11-01 | 0.82     | $10.14 Billion  |
| 2023-08-03 | 0.79     | $9.98 Billion  |
| 2024-07-31 | 0.79     | $9.98 Billion  |

* ABT's recent earnings have been relatively consistent, showing slight growth in revenue. 
* The most recent earnings report (2024-07-31) fell short of analyst expectations for both EPS and revenue. 
* This could explain the recent downward pressure on the stock price.

**5. News and Recent Issues:**

* **Recent Market Outlook:** ABT's stock price has been impacted by factors such as the ongoing macroeconomic uncertainties, rising interest rates, and investor concerns about the company's long-term growth prospects.
* **Analyst Opinions:** Analyst ratings on ABT are mixed, with some suggesting a hold or buy recommendation while others express concerns about the company's potential for continued growth.
* **Performance Highlights:** Despite some recent underperformance, ABT remains a strong performer in the healthcare sector, benefiting from its diverse product portfolio and global reach.

**6. Comprehensive Analysis:**

ABT is a well-established healthcare company with a strong track record. However, recent underperformance and a mixed market outlook have led to some investor concerns. The stock price has been under pressure in recent months, though it still shows potential for long-term growth.  The company's consistent earnings and its global reach remain attractive, but investors should monitor its upcoming earnings reports and its long-term growth trajectory. 

**7. Conclusion:**

ABT is a company with a strong market position and a long history of success. However, it faces challenges in the current market environment. Its recent underperformance compared to the S&P 500 and mixed market outlook warrant careful consideration before investing. Investors should monitor the company's future earnings reports and its strategic direction to assess its long-term potential. 
